Objectives: The purpose of this study was to assess the value of the serum levels of α-L-fucosidase activity in the diagnosis of patients with colorectal cancer. Methods: Using a fluorometric method we analyzed the α-L-fucosidase activity in preoperative sera from 137 colorectal cancer patients and in sera from 232 donors. Results: The enzymatic activity of α-L-fucosidase was significantly lower (p < 0.001) in patients (4.8 ± 3.09 U/ml) than in donors (10.5 ± 5.46 U/ml). Using the ROC curve, the ideal cut-off for the diagnostic value of α-L-fucosidase activity was determined to be 5.6 U/ml. The diagnostic efficiency for colorectal cancer of α-L-fucosidase activity was higher than that observed for carcinoembryonic antigen (cut-off 5.0 ng/ml), especially for tumors at an early stage. Conclusions: Our results suggest that preoperative serum α-L-fucosidase activity may be used as a cheap and easy complementary test, in addition to standard clinical procedures routinely used for the diagnosis of colorectal cancer.

Keywords:
Alpha-L-fucosidase, Colorectal cancer, Serum, Tumor markers, Diagnostic value
1.
Fenoglio-Preiser CM, Noffsinger G, Franzin G, Zamboni G, Scarpa A, Geboes K: Other tumours of the large intestine; in Whitehead R (ed): Gastrointestinal and Oesophageal Pathology. Edinburgh, Churchill-Livingstone, 1995, pp 405–425.
2.
Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andren-Sandberg A, Lindholm L: Sensitivity and specificity of CA242 in gastrointestinal cancer: A comparison with CEA, CA 50 and CA 19-9. Br J Cancer 1992;65:215–221.
3.
van der Schouw YT, Verbeek ALM, Wobbes T, Segers MF, Thomas CM: Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer 1992;66:148–154.
4.
American Society of Clinical Oncology: Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843–2877.
5.
Guadagni F, Roselli M, Cosimelli M, Mannella E, Tedesco M, Cavaliere F, Grassi A, Abbolito MR, Greiner JW, Schlom J: TAG-72 (CA 72-4 assay) as a complementary serum tumour antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 1993;72:2098–2106.
6.
Hall NR, Finan PJ, Stephson BM, Purves DA, Cooper EH: The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. Br. J Cancer 1994;70:549–553.
7.
Wang JY, Tang R, Chiang JM: Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272–277.
8.
Schwartz MK: Enzymes in cancer. Clin Chem 1973;19:10–22.
9.
Alhadeff JA: Structure and function of mammalian α-L-fucosidases. Trends Comp Biochem Physiol 1998;4:105–118.
10.
Abdel-Aleem H, Ahmed A, Sabra AM, Zakhari M, Soliman M, Hamed H: Serum alpha-L-fucosidase enzyme activity in ovarian and other female genital tract tumours. Int J Gynecol Obstet 1996;55:273–279.
11.
Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M, Bourel M, Legall J: Serum α-L-fucosidase: A new marker for the diagnosis of primary hepatic carcinoma? Hepatology 1984;4:889–892.
12.
Bukofzer S, Stass PM, Kew MC, de Beer M, Groeneveld HAT: Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Southern African Blacks. Br J Cancer 1989;59:417–420.
13.
Hutchinson WL, Johnson PJ, Du M, Williams R: Serum and tissue α-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. Clin Sci 1991;81:177–182.
14.
Marotta F, Chui DH, Safran P, Zhang SC: Serum α-L-fucosidase: A more sensitive marker for hepatocellular carcinoma? Digest Dis Sci 1991;36:993–997.
15.
Giardina MA, Matarazzo M, Varriale A, Morante R, Napoli A, Martino R: Serum alpha-L-fucosidase: A useful marker in the diagnosis of hepatocellular carcinoma. Cancer 1992;70:1044–1048.
16.
Takahashi H, Saibara T, Iwamura S, Tomita A, Maeda T, Onishi S, Yamamoto Y, Enzan H: Serum α-L-fucosidase activity and tumour size in hepatocellular carcinoma. Hepatology 1994;19:1414–1417.
17.
Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, De Marco G: Serum α-L-fucosidase activity and early detection of hepatocellular carcinoma. Cancer 1998;83:2468–2474.
18.
Dukes CE: The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323–332.
19.
Páez de la Cadena M, Fernández J, de Carlos A, Martínez-Zorzano V, Gil-Martín E, Rodríguez-Berrocal FJ: Low levels of α-L-fucosidase activity in colorectal cancer are due to decreased amounts of the enzymatic protein and are related with Dukes’ stage. Int J Oncol 1996;9:747–754.
20.
Gil-Martín E, Rodríguez-Berrocal J, Páez de la Cadena M, Fernández-Briera A: Alterations of glycosidases in human colonic adenocarcinoma. Clin Biochem 1997;30:17–25.
21.
Engel PC: Enzyme Kinetics. Types of assay procedure; in Engel PC (ed): Enzymology. Dublin, Bios Scientific Publishers, 1996, pp 77–83.
22.
Beck JR, Shultz EK: The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986;110:13–20.
23.
Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–577.
24.
Willems PJ, Romeo E, Den Tandt WR, Van Elsen AF, Leroy JG: pH-dependent association-dissociation of high and low activity plasma α-L-fucosidase. Hum Genet 1981;59:115–118.
25.
DiCioccio RA, Barlow JJ, Matta KL: Substrate specificity and other properties of α-L- fucosidase from human serum. J Biol Chem 1982;257:714–718.
26.
Eiberg H, Mohr J, Nielsen LS: Linkage of plasma α-L-fucosidase (FUCA2) and the plasminogen (PLG) system. Clin Genet 1984;26:23–29.
27.
Lombardo A, Bairati C, Goi G, Roggi C, Maccarini L, Bollini D, Burlina A: Plasma lysosomal glycohydrolases in a general population. Clin Chim Acta 1996;247:39–49.
28.
Takeshita H, Yasuda T, Nadano D, Iida R, Nakanaga M, Tenjo E, Sawazaki K, Kishi K: Genetically polymorphic α-L-fucosidase (FUCA1) isozymes detected in blood plasma. Hum Genet 1994;94:224–230.
29.
Harlow BL, Weiss NS, Holmes EH: Plasma α-L-fucosidase activity and the risk of borderline epithelial ovarian tumours. Cancer Res 1990;50:4702–4703.
30.
Fernández-Rodríguez J, Páez de la Cadena M, Martínez-Zorzano VS, Rodríguez-Berrocal FJ: Fucose levels in sera and in tumours of colorectal adenocarcinoma patients. Cancer Lett 1997;121:147–153.
31.
Kemmner W, Schlag P, Möller P, Brossmer R: Homotipic aggregation and terminal glycosilation of cells from dissociated human colorectal tumour tissue. Oncology 1992;49:63–67.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.